Literature DB >> 6341873

The treatment of myotonia: evaluation of chronic oral taurine therapy.

L Durelli, R Mutani, F Fassio.   

Abstract

A double-blind, single crossover study of chronic oral taurine administration versus placebo was conducted on nine patients with dystrophia myotonica. The severity of myotonia was assessed by clinical and electromyographic criteria and by testing the sensitivity of myotonic muscles to the intra-arterial infusion of potassium chloride. Confirming the antimyotonic effect of acute parenteral taurine, chronic treatment induced significant improvement of myotonia and a decreased sensitivity to the arterial potassium load as well as an enhancement of electrolyte movements across the membrane of the studied muscles. No significant side effects were noted.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6341873     DOI: 10.1212/wnl.33.5.599-a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  Evaluation of taurine neuroprotection in aged rats with traumatic brain injury.

Authors:  Raeesa Gupte; Sarah Christian; Paul Keselman; Joshua Habiger; William M Brooks; Janna L Harris
Journal:  Brain Imaging Behav       Date:  2019-04       Impact factor: 3.978

2.  Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

Authors:  E L Logigian; W B Martens; R T Moxley; M P McDermott; N Dilek; A W Wiegner; A T Pearson; C A Barbieri; C L Annis; C A Thornton; R T Moxley
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

Review 3.  Guidelines on clinical presentation and management of nondystrophic myotonias.

Authors:  Bas C Stunnenberg; Samantha LoRusso; W David Arnold; Richard J Barohn; Stephen C Cannon; Bertrand Fontaine; Robert C Griggs; Michael G Hanna; Emma Matthews; Giovanni Meola; Valeria A Sansone; Jaya R Trivedi; Baziel G M van Engelen; Savine Vicart; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2020-05-27       Impact factor: 3.217

Review 4.  Drug treatment for myotonia.

Authors:  J Trip; G Drost; B G M van Engelen; C G Faber
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

Review 5.  Taurine: the appeal of a safe amino acid for skeletal muscle disorders.

Authors:  Annamaria De Luca; Sabata Pierno; Diana Conte Camerino
Journal:  J Transl Med       Date:  2015-07-25       Impact factor: 5.531

6.  The Effect of Taurine on the Recovery from Eccentric Exercise-Induced Muscle Damage in Males.

Authors:  Yanita McLeay; Stephen Stannard; Matthew Barnes
Journal:  Antioxidants (Basel)       Date:  2017-10-17

Review 7.  Taurine and skeletal muscle disorders.

Authors:  Diana Conte Camerino; Domenico Tricarico; Sabata Pierno; Jean-François Desaphy; Antonella Liantonio; Michael Pusch; Rosa Burdi; Claudia Camerino; Bodvael Fraysse; Annamaria De Luca
Journal:  Neurochem Res       Date:  2004-01       Impact factor: 3.996

Review 8.  Effects and Mechanisms of Taurine as a Therapeutic Agent.

Authors:  Stephen Schaffer; Ha Won Kim
Journal:  Biomol Ther (Seoul)       Date:  2018-05-01       Impact factor: 4.634

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.